Abbott Laboratories

Good morning and thanks for joining us. Also on today's call will be Tom Freyman, our Executive Vice President, Finance and Chief Financial Officer.

Tom will review the third quarter results and I will discuss the business operating highlights as normal. Following our comments, we will take any questions that you have.

Some statements made today may be forward-looking. Abbot cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

Factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our 2007 Form 10-K. We undertake no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

In today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measure in our earnings news release and regulatory filings from today, which will be available on our website at abbott.com.

So with that, I will now turn the call over to Tom. Tom?

Thanks John and good morning. Today we're pleased to report third quarter results that beat expectations with high-teens sales and earnings growth.

Diluted earnings per share of $0.79 were above our previous guidance range of $0.76 to $0.78, reflecting EPS growth of nearly 18% over the prior year. We are also pleased to be raising our EPS outlook for the full year 2008.

Sales for the quarter were $7.5 billion, an increase of more than 17%, also ahead of our previous forecast. As a result of our performance to date and our outlook for the remainder of the year, today, we are again raising our full year ongoing earnings per share guidance range to $3.31 to $3.33, up from the previous range of $3.24 to $3.28.

The midpoint of this new guidance range reflects nearly 17% growth. With this performance, we're clearly seeing the results of our efforts as we build Abbott into a global, diversified healthcare company with recognized market leadership positions and top tier financial performance.

We've differentiated ourselves from our peers with multiple core growth franchises, significant cash flow and a diversified base of earnings. We're well positioned to continue to deliver double-digit earnings growth while investing to sustain growth into 2009 and beyond.

We believe we provide a unique blend of both safety and growth in this difficult market environment. Our Board of Directors recently authorized a new $5 billion share repurchase program.

Last year, we returned more than $3 billion to shareholders through share repurchases and dividends and we're on track to exceed that level in 2008. We expect record operating cash flow for the full year 2008 and we increased our dividend by nearly 11% earlier this year.

Turning to the specifics of our quarterly results. Our sales growth of 17.6% this quarter included a favorable 4.7% effective exchange rate.

Results were strong across each of our global businesses with pharmaceuticals, diagnostics, vascular and nutritional all contributing double-digit sales growth. We also see good performance from our key growth drivers.

This includes XIENCE, which is off to a very strong start in the first quarter of its U.S. launch; HUMIRA, which was up 50% worldwide; double-digit growth in our lipid franchise and more than 22% growth in international nutrition.

John will discuss these in more detail in his review of the business operating highlights. The adjusted gross margin ratio in the quarter was 57.5%, at the high-end of our guidance range.

Total R&D and SG&A as adjusted increased more than 13%, reflecting investment spending across the businesses in part to support the launches of new products and indications as well as continued investment in our broad-based pipeline. The tax rate this quarter was 21%, in line with our previous forecast.

As a reminder, the U.S. R&D tax credit was not enacted until October so it had no impact on our third quarter rate.

Now let's turn to the outlook for the remainder of 2008. As I mentioned, today we're raising our 2008 earnings per share guidance to $3.31 to $3.33, the midpoint of which would be growth of almost 17%.

In fact, our EPS guidance was up approximately $0.10 per share from our original guidance provided in January. Sales growth for the full year is expected to be in the mid teens.

Now let me walk you through some of the key P&L line items as we forecast them for the fourth quarter. We expect sales growth in the low double-digits including an estimated 2% negative impact from exchange, a gross margin ratio of around 59%, continued strong investment in the business with SG&A and R&D both up low double digits and other income of approximately $125 million, reflecting ongoing payments from Takeda following the conclusion of the TAP joint venture.

The fourth quarter tax rate is expected to be between 18.5% and 19%, which reflects our current 21% rate less the full year impact of the R&D tax credit. So in summary, our global, diversified business strategy is delivering strong results.

It's based on competing in high growth markets where product differentiation drives market success. The products within our core franchises, HUMIRA, XIENCE, international nutritional, our lipids portfolio and the compounds in our pipeline are all examples of the success of our strategy.

We are very pleased with our third quarter performance. We reported strong sales growth, more than 17%...

of more than 17%, EPS that beat our original guidance and we raised our earnings per share guidance range for the full year. And we expect this strength to continue into 2009 as we continue to target another year of double-digit EPS growth.

With that, let's turn to the business operating highlights. John?

Thanks Tom. This morning I'll review the quarterly performance of our major business segments: pharmaceuticals, nutritionals and medical products including Abbott Vascular, Diagnostics and Diabetes Care.

So let me start with our medical products businesses where sales in the quarter increased more than 25%. In our Vascular business, global sales were $636 million in the quarter, an increase of 58%.

We saw especially strong growth in our worldwide coronary stent business, which had sales of $383 million. In the U.S., coronary stent sales were driven by rapid uptake of our drug-eluting stent XIENCE V, which, as you know, we launched in the U.S.

in July. The launch, while still early, has led to steady market share gains as XIENCE continues to gain share at the expense of all of the three major competitors.

XIENCE is clearly the product of choice among interventional cardiologists based on its unprecedented clinical data, which continues to get better and best-in-class deliverability, confirming that physicians are viewing XIENCE as a truly next-generation drug-eluting stent. This week at the TCT Interventional Cardiology meeting, we presented two year results from the meta-analysis of our XIENCE clinical trials, SPIRIT II and SPIRIT III.

This data confirms that XIENCE V continues to deliver clinically significant outcomes for patients compared to TAXUS, outperforming TAXUS in key efficacy and safety endpoints out to two years. The differences between XIENCE and TAXUS grew between one and two years, reinforcing the long-term safety and efficacy profile of XIENCE.

This includes a 45% reduction in major adverse cardiac events or MACE; a 41% reduction in heart attack or death and a 41% reduction in revascularization. This strong clinical data is being well accepted in the market.

In just three months, XIENCE has become the number one stent on the U.S. market with share in the mid to upper 20s.

The XIENCE platform which includes PROMUS has become the most popular stent platform in the U.S. with more than 50% market share.

PROMUS is the private label version of XIENCE distributed by Boston Scientific. And as a reminder, we benefit economically from Boston Scientific's sales of PROMUS.

Looking at the DES market broadly, we're very pleased to see continued, steady improvement. U.S.

DES penetration has now surpassed 70% in the U.S. PCI [percutaneous coronary intervention] volumes have also improved, up in the mid single digits versus the third quarter of last year.

Outside of the U.S., we also continue to make steady progress with XIENCE. In Western Europe, XIENCE share alone has surpassed CYPHER, ENDEAVOR and now TAXUS to claim the number one market leadership position.

In total, XIENCE V is now the leading drug-eluting stent across all geographies in which it's been launched. We filed for Japanese market approval earlier this year and look forward to expansion into this market with a launch towards the end of next year, 2009.

As a result of the successful U.S. launch, the continued shared gains outside of the U.S.

and the recent improvements in the overall DES market, our DES franchise revenues this quarter outperformed our expectations with $305 million in combined sales. As a reminder, DES franchise sales include global XIENCE sales as well as other third party DES product revenues.

This includes the royalty revenue we received from Medtronic on ENDEAVOR as well as revenue we received from Boston Scientific of course on sales of PROMUS. So as we look ahead to the forth quarter, we expect global vascular sales to continue to grow strong double digits.

Now let me turn to our worldwide Diagnostics business where sales grew more than 15% this quarter, representing strong revenue growth in all three Diagnostic segments: core diagnostics, molecular diagnostics and point of care diagnostics. We saw double-digit growth both in the U.S.

and internationally in our core diagnostics segment again this quarter. This was the result of continued strong growth of both our PRISM blood analyzer as well as our ARCHITECT immunochemistry system.

We've launched new ARCHITECT systems including the i1000 for smaller labs and the c16000 for large labs. In the third quarter, Abbot submitted for U.S.

FDA approval of our ARCHITECT core hepatitis test. Approval of the core test would complete our hepatitis B panel of tests in the U.S.

and represent an important milestone in the expansion of ARCHITECT's automated hepatitis testing menu. Abbot submitted for FDA approval its PRISM HIVO Plus assay, a fully automated blood screening test designed to detect HIV-1, HIV-2 and HIV Group O and serum and plasma.

This assay will further enhance the panel of screening tests in our highly successful Abbott PRISM blood screening instrument for the U.S. market.

Also in the quarter, we announced plans to improve profitability in our core diagnostics business. These actions support our efforts to reduce overall costs, improve efficiencies and expand margins.

We've seen improved margins already this year and expect that improvement to continue as we anticipate doubling profit and cash flow in this particular business over the next several years. In our point of care business, sales grew more than 15% in the third quarter.

Growth was driven by strong sales across all segments as well as successful execution in both large U.S. hospitals and alternate site locations.

Abbott's i-STAT analyzer is now used in one out of every three U.S. hospitals and in more than 500 emergency rooms.

And in molecular diagnostics, sales this quarter increased more than 35%, driven by strong growth of both the m2000 and our Vysis products. In the U.S., we've submitted for FDA approval of our hepatitis B assay for the m2000.

And outside of the U.S., we've received CE mark for the HPV assay on the m2000, which we planned to launch in Europe next month. So looking ahead to the fourth quarter in our worldwide Diagnostics businesses, we anticipate mid single-digit growth, which includes the impact of foreign exchange.

In Diabetes Care, sales in the quarter increased more than 10% globally, driven by strong international sales and increasing adoption of our new no-calibration meters, FreeStyle Lite and FreeStyle Freedom Lite which eliminate the manual calibration step required by most glucose meters, improving convenience for those people living with diabetes. In the quarter, we saw positive share results from the promotional program we initiated last quarter and continued prescription share gains of our FreeStyle meters.

In the U.S., sales growth this quarter were impacted by the comparison to the prior year and FreeStyle Lite launched. Adjusted for initial shipments for last year's launch, growth this quarter in the U.S.

approached about 10%. Outside of the U.S., we continue to see strong growth internationally.

In emerging markets, Abbott is the number two player and our sales are growing more than 20%. In the fourth quarter, we expect high single digit growth worldwide in Abbott Diabetes Care, which also includes the impact of foreign exchange.

In our global nutritionals business, sales this quarter were up more than 14%, driven by more than 22% growth in international nutritionals. We continue to see double-digit growth across both pediatric and adult nutritional products internationally, particularly in emerging markets such as Latin America and Asia where population growth and improving economies are leading to increased demand for our high quality nutritional products.

In the U.S., we recently launched Similac Advance EarlyShield, a new and improved formulation in a new and redesigned package. Developed to be more like breast milk, it's the first and only infant formula with a unique blend of prebiotics, nucleotides and antioxidants to improve a baby's immune system.

In the fourth quarter, in our nutritionals business, we expect mid to high single-digit growth in the U.S. and continued double-digit growth, strong double-digit growth internationally.

Turning now to our global pharmaceuticals business where sales in the third quarter increased nearly 17%, driven by more than 21% growth in international pharmaceuticals and nearly 13% growth in our U.S. business.

Several key products drove performance this quarter. So let me start with immunology where worldwide HUMIRA sales this quarter were up 50% to $1.2 billion including 67% international growth.

We're obviously very pleased with the results of our launch in the psoriasis market where we've exceeded expectations on a number of launch metrics. In less than eight months since our FDA approval for this indication, HUMIRA total prescription share has gained approximately 15 share points and is now approaching 30% total share.

New prescription share now exceeds 30%. HUMIRA is now capturing nearly as many self injectable new to brand psoriasis patients as the market leader.

And more than 4200 dermatologists have now written prescriptions for HUMIRA. Our early success in this market is based on differentiating clinical data.

Data from the pivotal REVEAL study demonstrated that more than 70% of HUMIRA psoriasis patients achieved a 75% reduction in their symptoms and, quite frankly, a remarkable 20% of patients achieved a 100% reduction or complete clearance. During the quarter, we presented data from a sub-analysis of the REVEAL study demonstrated continued strong efficacy and safety of HUMIRA in psoriasis patients.

The findings showed that HUMIRA works effectively irrespective of the patient's age, duration of disease, whether they have been diagnosed with psoriatic arthritis or have a recent history of systemic therapy. The data also showed continuous long-term therapy with HUMIRA is more effective than interrupted therapy.

HUMIRA efficacy in both psoriasis and psoriatic arthritis compares favorably to existing agents or potential new mechanisms of action being investigated. Based on outstanding clinical data with HUMIRA and more than a decade of clinical experience, we are well positioned for continued success in the growing dermatology market.

U.S. growth HUMIRA in all specialty segments, rheumatology, dermatology and gastroenterology continues to outpace the market, contributing the majority of growth...

of market growth since January. In Crohn's, HUMIRA total prescription market share now exceeds 40% and our base RA business is also demonstrating consistent performance and is poised to take over the number two market share position by the end of this year.

Internationally, HUMIRA secured the number one market share position in Australia recently and became the top selling pharmaceutical in Germany and was launched also in Japan where we received approval for RA during the second quarter. HUMIRA continues to represent a major growth driver for Abbott in the coming years with significant opportunity remaining in both the U.S.

and international markets. Outside of the U.S., penetration rates are currently in the single digits for biologics in many of these disease categories.

The global biologics market for all HUMIRA indications is now estimated to exceed $20 billion by the year 2012. Later this month, the American College of Rheumatology Meeting will present data regarding HUMIRA's ability to inhibit joint destruction out to five years in patients with early RA.

As a reminder, we already have five year radiographic data in our label for established RA patients. HUMIRA is the only biologic with proven long-term radiographic inhibition data in both patient types.

Based on the strong performance to date and the outlook for continued momentum with HUMIRA, we now expect full year 2008 global sales for HUMIRA of more than $4.4 billion. In our lipid management franchise, Abbott's growth in the dyslipidemia market continues to outpace the overall cholesterol market with double-digit growth of both Niaspan and TriCor.

Niaspan sales were $194 million in the third quarter, up more than 16%. Currently, more than 1 million patients are on Niaspan therapy.

TriCor sales in the quarter were $334 million, up 11%. During the quarter, we announced an agreement with AstraZeneca under which Abbot's TriCor sales force will co-promote CRESTOR in the U.S.

This agreement represents a complement to Abbot's growing lipid management franchise and strategically positions the sales force with the TRILIPIX, CRESTOR fixed dose combination that is currently in late stage Phase III development. Over the past few years, we've taken a number of strategic steps to strengthen our position in the overall dyslipidemia marketplace.

Our 2006 agreement with AstraZeneca to develop a fixed dose combination with CRESTOR, the acquisition of Kos and the development of TRILIPIX. We've established Abbot as a significant player with a portfolio uniquely positioned to address the growing need for adjunctive and combination therapies.

So for the fourth quarter looking ahead, we continue to expect strong double-digit growth in our lipid franchise. Moving on to antivirals where Kaletra was up double digits worldwide in the quarter to $387 million, driven by continued success of the tablet launch in various international markets.

And Lupron in the quarter had sales of $149 million, reflecting the first full quarter of sales following the conclusion of the TAP joint venture earlier this year. We expect a similar level of Lupron sales in the fourth quarter.

So in summary, in pharmaceuticals, for the fourth quarter, we expect double-digit sales growth for our domestic pharmaceutical businesses and high single-digit growth internationally, which includes the impact of foreign exchange. Finally, our broad-based pipeline continues to be highly productive.

As Tom mentioned, we had eight new regulatory approvals this year alone, including four approvals in our global pharmaceutical business and four approvals in medical products. This quarter we anticipate FDA approval of TRILIPIX, our next-generation fibrate.

Once approved, TRILIPIX will be the first and only indicated for combination use with a statin. Our regulatory submission includes data from three combination studies along with the 52-week long-term open label extension study, all part of the largest clinical program to date designed to evaluate the efficacy and safety of a fibrate in combination with three major statins.

Data from these studies demonstrate that TRILIPIX in combination with the three most commonly prescribed statins: LIPITOR, ZOCOR and CRESTOR improved HDL and triglycerides compared to statin therapy alone and significantly improve LDL compare to TRILIPIX alone. And importantly, combination therapy was well tolerated with reported safety similar to monotherapy.

Also this quarter, we anticipate approval of our extended-release form of Vicodin. When approved, this product will be the first extended-release formulation of hydrocodone with acetaminophen.

Vicodin is one of the most established treatments in pain medicine and is the most prescribed product in the U.S. with more than 100 million prescriptions written annually.

With the ongoing productivity and success of our late stage pipeline, we're now focused on our early to mid-stage opportunities. In pharmaceuticals, we continue innovative research programs in our therapeutic areas of focus which include oncology, neuroscience, immunology and hepatitis.

We have a number of unique compounds in development that represent truly novel science and, if successful, would result in significant advances in treatment for patients. We're also focused on expanding our medical products pipeline with new products and packaging in our nutritionals business, new diagnostic systems and tests and developments...

significant developments in our pipeline for our Vascular business. We're working on a next-generation XIENCE DES platform to further improve deliverability, particularly in longer lengths.

We're capitalizing on the proven clinical benefits of the XIENCE V polymer and drug, an improved stent and a delivery system. In addition, we are the market leader with our bioabsorbable drug-eluting stent that's in development.

At TCT this week, we presented two year data from our ABSORB clinical trial that showed our drug-eluting fully bioabsorbable stent successfully treated coronary early disease and was absorbed within two years. Patients experienced no new major cardiac events and no stent thrombosis.

And what's truly impressive for us is the trend in the data showed at two years a blood vessel moved and functioned like a normal blood vessel, a result that's not possible with metal-based implants. Abbott is the only company with long-term clinical data evaluating the safety and performance of fully bioabsorbable drug-eluting coronary stent.

So in summary, we are very pleased with our strong and diversified performance this quarter with double-digit sales growth reported in each major global business and adjusted earnings growth of nearly 18% over the prior year. Our underlying businesses are strong, our core growth franchises are healthy and at the same time, we're investing to sustain this performance into 2009 and beyond.

And so with that, we'll open up the call, operator, for questions. Question And Answer

It's Goldman Sachs. Good morning guys.

Good morning.

Hey Tom, as you made your comments and gave us some read through to your expectations for 2009, which is for double-digit earnings growth, could you just walk us through sort of what parts of the Abbott business you believe could be sensitive to a global slowing in GDP and what steps you might have available to you to offset any growth there to continue to ensure that you can get that double-digit growth?

Yes, Larry, sure. When I talk about double-digit growth, it's really driven by the momentum we're seeing in all of these businesses.

I mean if you go through the quarter, we're performing really across the board very well in all of our businesses. And that gives me a lot of confidence in our ability to continue to grow the earnings of this company in line with the investment identity we have and really the targets we've repeatedly stated.

So fundamentals there are really just what's going on in the businesses and how well we're executing and really the portfolio of products we have to be able to deliver that kind of growth. I think Abbott...

we have not seen anything to date on counting the economy and an impact on our business. In pharma, we're very specialty focused, and those are long-term chronic disease areas that are very immune to economic activity and we have very little exposure, as you know, to things like discretionary consumer products.

So we haven't seen much and I think our business is going to be quite different than most because of the types of areas we do business in.

And Tom, just one of the growth drivers, that's been very nice and strong for you guys has been that international nutritional business. Again, how much exposure there is due to consumer if you look at some of those zone bars and other things that people might stop...

not stop buying? I suspect it's pretty small overall.

It's pretty much the same as what I said on the other businesses. First of all, I think any concern of economic slowdown is a little more U.S.-focused as I recall all the various economists and the like.

International growth in these markets has continued to be very, very strong. And that one product you mentioned is a very, very minor product for us in the international market.

So anyway, really, what's driving that is the base product, the pediatric nutritional, the adult nutritionals that people really see as more core to their essential as opposed to discretionary type items. So I think in that business as well and as we've forecasted '09 as we go through our reviews here, we continue to feel very good about the ability of these markets to grow and our products to continue to gain share and the fact these products are pretty resilient.

Okay. And then one other question, which is as look at your cash balances, obviously lots of challenges out there in the credit markets.

Could you just, for the benefit of all of us, just give us a sense of what that cash balance really is sitting in and perhaps any exposures to any securities within some of the subprime mortgages? And I guess along with that question is sort of how has your commercial paper funding been going?

Are you getting access to that? And then John, just a quick clarification, the forth quarter sales guidance that you gave for growth, it sounded like that already included the impact of currency, but I just wanted to make sure I heard that correctly.

On the credit market situation, as you know, we are very conservatively managed from a financial perspective. The deposits we have and the cash we have invested are in very, very high quality instruments.

And we've even obviously become even more cautious in the last few months in terms of selecting where we put our money. We have absolutely no exposure to any of the types of exotic instruments that you talked about, and there is absolutely no issue there.

And as a very strong credit [ph], we have been really unaffected by the turmoil in the credit markets. We've had no problems whatsoever issuing commercial paper at very attractive rates.

And I think we are the type of credit, the way I read into this is we are the type of credit people are looking for in this type of market. And we've got a $4 billion essentially unused backup credit line.

We have no plans and have not drawn anything on that because we have great access to the commercial paper market. So we are in great position from a credit perspective and have been really unaffected by the turmoil in the market.

Okay, excellent.

Yes, Larry, just to clarify, this is John. Yes, all the numbers and forecast that I gave for the fourth quarter include the impact of exchange, which, at this point, top of the house, corporate, we expect to be unfavorable, about 2%.

So when we look at the total company and growth into the fourth quarter, we expect sales growth of low double-digits, that accounts for a roughly 2% unfavorable impact from exchange.

Excellent. Thanks very much guys.

You're welcome.

Thank you, it's JPMorgan. A few questions.

Just wanted to clarify on the pipeline. First, you seem relatively confident in the near-term approvals for Vicodin CR and TRILIPIX.

Can you comment on when you think you'll have this submission into a combination of TRILIPIX plus CRESTOR?

Yes, we talked about that being a later, next year, second half '09.

Okay. And that's...

so the assumption is still a back half of '09 event?

Correct. Yes.

And if that changes, I'll let you know. Obviously, we like to be conservative when we give our forecast.

So we'll see. We're moving along nicely.

Let me push you just for a minute on... make sure I understand some the numbers you ran off, Tom, on the fourth quarter and full year updated guidance.

You mentioned $125 million of other income. Was that...

that was for the fourth quarter, right?

That's correct.

And what is that attributable to? Where does that comes from?

That is all the payments from Takeda associated with the TAP wind down. As we've said at the beginning of the year, we went from a joint venture income situation and income in the...

I don't know... north of $350 million to this approach where we're taking payments from Takeda associated with Prevacid and pipeline products.

And that number in the fourth quarter would bring us pretty close to the full year number we've been taking about all along. We are actually a little bit higher because the performance has been a little better than we conservatively forecasted.

So that's entirely due to the TAP activity.

Got you. And then, so if I think about you're changing your guidance, you're raising your guidance here for the full year, it would look to me like you're still being on the conservative end.

The R&D tax credit, so if we start with $3.24 to $3.28, which is where you were, the R&D tax credit would seem to add $0.03, the other income would appear to add $0.04. So even without the beat from this quarter, you would seem to already be at or even pushing above the high-end of your old guidance and so what's [ph] the beat from this quarter?

Let me clarify a couple of things there, Mike. R&D tax credit $0.02 to $0.03, something like that.

We'll see exactly what the number comes in when we close out the year. The TAP...

the other income has always been part of our forecast. That's not really an add to our previous guidance.

That's consistent with our previous guidance. So it's pretty much seeing the momentum in the business from the third quarter, flowing that through.

The R&D tax credit is helping in the fourth quarter. But overall, it's a better, certainly a better fourth quarter forecast than we provided back in the second quarter even adjusted for the R&D tax credits.

Okay. So you had that 125 of other income.

We did not, but you did.

Absolutely, not [indiscernible]. Yes, at the beginning, we've provided that full year number and, as I...

as we've said all along, it's a little bumpier than the income from the TAP joint venture. We've been forecasting the quarterly amount somewhat conservatively.

But if you add up all the quarters on that, it's very consistent with our guidance.

Okay, last question. On the share authorization which you announced I think on Monday, when does your window open up post the quarter just start to act again on your buyback?

Shortly after the quarter. Once obviously the news from today's earnings is out and absorbed by the market, we can move forward at any time we choose.

Okay. Great, thanks Tom.

Thank you.

Good morning, it's Rick Wise, Leerink Swann.

Good morning.

Good morning Tom. A couple of...

let me hit on some pharma questions. First of all, if I remember correctly, second quarter saw some inventory destocking dragging on pharma sales, if I remember, particularly HUMIRA.

Did... was there any offset or rebound in third quarter as wholesalers rebuilt inventory?

No. I mean if you look at the script data on HUMIRA, it's pretty consistent with that plus a modest amount of price.

So if you take those two things, it was growing. The last monthly script data showed we're growing in the low to mid 20s...

or 30s, excuse me.

Okay. HUMIRA, obviously a major growth driver, and I was struck, John, by your commentary.

I think you were saying the global biologic market $20 billion, emphasizing I assume a lot of opportunity for growth for HUMIRA. But there is competition looming.

We all listen to J&J highlight ustekinumab for psoriasis, golimumab for RA. Just in general, does new competition or the very size of HUMIRA slow HUMIRA growth as we look out over the next couple of years?

Or are you optimistic that the new indications and the under penetration in the inhibitor [ph] market continued growth roughly current levels? So just any perspective would be welcome.

Sure. Obviously, with HUMIRA now being on the market and having more than 10 years of data, all the data that we've showed and have demonstrated with HUMIRA in all these different indications, it's clearly now the best-in-class TNF inhibitor considered the gold standard, and it's growing at a very nice rate.

We expect growth to continue strongly over our five year long range plan. So there is significant growth opportunity with the product that accounts for market growth that accounts for further penetration and launch of these products in different countries.

There is new competition, as you noted. That's all accounted for in that outlook.

All these products have different challenges. They have a place in the market.

For different reasons, they're either IV formed products that have limited convenience and/or don't have the efficacy or safety that HUMIRA has and be so probably reserved for salvage or backup therapy, or they have other limitations. And I think in particular the competitive product that is in the FDA's review right now for self injectable does not provide any really additional clinical efficacy benefit from what we've seen with HUMIRA.

In fact, our scores of HUMIRA, the ACR scores, are actually better than this particular product. And obviously, you've got a longer track record of safety and most importantly, five year radiographic progression data in the label, which is very important.

So if you look at the normal patterns of pharmaceutical launches, products that are fourth, to fifth or sixth to market that do not offer any clinical advantages typically have a limited place in the market. So on the other hand, that promotional effort into the market in helping educate patients and physicians will probably help sustain market growth.

Because we're not seeing a whole lot of that from our primary competitor this year, we are having to do a lot of that ourselves. So that's the other side of that coin.

So I'd say overall growth of HUMIRA factors in these different competitors, none of which offer any advantages that HUMIRA doesn't already have.

Okay. Two last quick ones.

J&J highlighted their... said that DES prices have declined 3% sequentially in United States yesterday.

Just wondering what you're seeing in pricing environment? Is it that bad or...

and second, you highlighted the diagnostic restructuring. Operating margins, I recall, now are in the upper single digits.

Where can they go over the next couple of years? I assume this is an important driver of continued margin expansion at Abbott?

Yes, let me take you're first question and then I'll let Tom talk about diagnostic margin expansion. So pricing actually from the data that we have in our own market data as well third party data continues to show that the leading products, which is obviously now the XIENCE platform, XIENCE / PROMUS prices being maintained at a very high level.

And this is a premium price product because it has the best data out there. As we've talked about before, no other product has shown superiority and all the other attributes that we've talked about that make it so appealing to interventional cardiologists.

So actually the price of both XIENCE and PROMUS has been well maintained, average price in the market around that 2000 to 2100 in that range. So I can't speak for some other competitive products.

We don't have the most recent shared data and price information on I think the product you're talking about from one of our competitors. So I don't have any indications, or we don't have any indications that there has been any major price play in this marketplace.

But I don't have the most current information. There is always pockets of discounting that go on, but certainly nothing significant.

Price has been well maintained and most importantly, I think the market is growing again with DES penetration now in the 71%-72% range. PCI volume has moved up nicely to the mid single digits here in the last data point that we have.

So it's an expanding market, XIENCE obviously doing extremely well, already the leading product and a lot of growth still left with the platform as we go out into next year, so.

I'll take the ADD question there, Rick. As you mentioned, we were in the high single digits in the segment in '07.

Already in the first three quarters of the year, you are seeing that op margin move into the low double-digit area. And in the third quarter, you will see in the Q when it comes out that we continue to be in that area.

So we're making very nice progress within the division in terms of profitability improvement program. And we've talked about with all the things that are working on there, basically doubling the profitability of this business over the next four or five years.

And we would expect that to move into the mid to upper teens from an op margin perspective out in that timeframe. I think it'll be a little bit slower progress in '09 just because they're going through a lot of the product transfers and the like that year.

But certainly, it will accelerate beyond '09. So things are looking very good in terms of op margins within diagnostics.

Sounds good. Thanks Tom, thanks John.

Thank you.

Morgan Stanley. Good morning.

Good morning.

Few quick questions here John. First of all, on Depakote, obviously, a little better than our expectation.

Is this simply a matter of timing or are we seeing anymore stickiness in either ER or epilepsy proper [ph]

Actually, Dep... just to reground everybody, Depakote is a product that...

one form of the product that accounts for about 50%, a little more than 50% of the total sales, went generic July 29th as expected. This was in our plans and in our forecasts for all of our growth expectations for this year and next.

That's tracking right in line with our expectations for the quarter. So the U.S.

sales for the third quarter were $254 million, and that was pretty much as we expected. So we'll go into next year.

That's accounted for in the double-digit growth outlook that Tom mentioned earlier in his comments for 2009. That is already anticipated, the effect of that next year.

Okay And John as well, on DES strategy, when shifting from the third to fourth, it seems as if on initial launch both parties sort of played nice with Boston focusing more on TAXUS accounts, perhaps Abbott going more after CYPHER accounts. Do you see any material changes in sort of sales force strategy and distribution from third heading into the fourth quarter?

No, really, we're in the enviable position I guess of taking share from everybody. Clearly, we've taken a significant amount from CYPHER.

And as you note, we've seen Boston Scientific cannibalizing a lot of their own TAXUS business with PROMUS. But we're taking a fair amount of share across the board from all three of the major players including ENDEAVOR.

We expect that to continue as we move into the fourth quarter and we expect DES sales as we go through the fourth quarter to maintain at this rate in terms of moving up steadily and share moving up steadily. We gained about two share points as we moved from August to September, and we're moving more towards that 30% XIENCE only share point in the market in the U.S.

and we're in a good path to get there.

Okay. And then I guess two quick ones here for Tom.

Tom, when we think about leverage in the business, given the trends we are seeing in HUMIRA and obviously XIENCE is going to probably approach peak margins faster than we thought, I think you've historically talked about margins won't back up '09 [ph] heading into 2010 real inflection in the middle part of the P&L or broader corporate leverage. Any changes to sort of that outlook given what you're seeing in the core business?

No, I mean as I've talked about, the last several years have been a period of building up funding levels to be sure we were competitive in all our markets. And we actually have seen SG&A go up as a percentage of sales.

And 2008 was a critical year for that given all the product launches we have and it was very important to spend appropriately to be sure those products went to market properly. But starting in '09, we continue to believe that there will start to be some leverage in the SG&A area because, to your point, the key products are growing very nicely and we're at competitive levels and we really think the sales will go up faster than the SG&A.

And one quick leverage question following Rick's question on diagnostics. The improvement in profitability is not surprising.

I guess what's surprising is the ability to improve profitability with growth still staying strictly [ph] slight above industry averages. Is it possible that you could take up margins in diagnostics and still maintain above market growth rates?

Certainly, I think that's possible. As I have talked about in the last year or so, the focus of the division has been much more on profitability and cash flow than it has been on growth.

But a bp, two, we've been pleasantly, pleasantly surprised with the excellent execution across that business on the commercial side as they focused them in these cost areas. And it seems like they have done a really good job doing both.

And as John mentioned, products like PRISM have done very well. So I think there is even more to be optimistic about in terms to the performance of that business going forward.

Great. Thanks for the color.

Thank you very much.

Thank you.

Hi, RBC Capital Markets. Good morning.

Good morning.

My first question relates to the expected uses of cash. Obviously, the $5 billion share repurchase program is considerably bigger than what we have been accustomed to from Abbott in recent years.

Does this in any way a signal of change in management's thinking about how it will return cash to shareholders and just talk little bit about what your intentions are regarding the dividend going forward and other uses of cash? And the final part of that is whether the declines that we've seen in healthcare asset values in recent months, whether that tempts to you to be any more aggressive on the M&A front than you might have been in the past?

Yes. Thanks Phil.

The $5 billion repurchase authorization is larger, quite a bit larger than what we've done in the past. And that really is a statement to our shareholders that we have a long-term commitment along with strong dividend payouts and an ongoing share repurchase program return a lot of cash to shareholders.

And the $5 billion is certainly a longer term perspective. One thing the timing of that allowed us to do is to take advantage of what is clearly a great buying opportunity right now in terms of our own share price.

And we can be a little more flexible in the short run to either at a bare minimum accelerate what we would have done over the next year or two and bring some of it forward at much more attractive prices and either take more shares out or use less dollars to do it. So it's really reflective of our long-term commitment and not really reflective of a fundamental shift in our strategy in terms of the cash utilization.

It continues to be the same. We value an increasing dividend, we have a high dividend payout, we have ongoing sale repurchase programs, we have been bringing debt down a little bit in the...

quite a bit actually in the last couple of quarters. So we've been using some cash for that.

So it's a nice balance and we're in a very, very good position from a cash flow perspective. Regarding M&A, certainly, some of the assets out there are quite more attractive from a price perspective.

But I don't think that fundamentally alters the motivation. When you are looking at a business long term, you've got to be sure there is a payback and it's a market you want to participate in at a more attractive price than might be a slightly better return.

But I don't think it fundamentally changes a decision whether to do an acquisition or not.

Great. Thanks Tom.

And following up on some of the operating margin improvement questions so far, I think one of the most intriguing opportunities is obviously in the Vascular division. Can you talk about where that division's level of profitability is right now?

Are we in kind of the second or the fourth inning in terms of what that could contribute in terms of operating margin improvement?

I think we're in the second batter, but I'll let Tom answer that.

You will see in the segment information we've put in our Q that Vascular really had a great quarter from a profitability perspective. It's into the double digits.

And as we've talked about, with the volume and the sales growth obviously and the volume running through our facilities, we expect very significant improvements in profitability in 2009. This is a major contributor to our growth.

And even in 2009, we think we're going to be approaching the 20% level in terms of operating profitability, which is a good step on the way to even doing better. So there is a long way to go there and we're going to see a lot of benefit in 2009.

Great. Well, batter up.

Last question and I'll leave you alone for now. To what degree, if any, does your Q4 outlook depend on the approvals or launches of TRILIPIX or Vicodin CR, and to what degree are you confident about those approvals in the fourth quarter?

Yes, I mean as we indicated, we continue to expect fourth quarter approvals of those... both of those products to be never good to be too aggressive in your financial planning.

And we're really not dependent on the precise timing of those within the fourth... to define during the quarter.

Okay. Thank you very much.

UBS. Thanks for taking my question.

Could you gentlemen provide a little elucidation about economic sensitivity, specifically with regards to the biologics which are, as you know, expensive? What about the...

is it something about the insurance profile or the lack of deductibles that gives you the confidence to think that the U.S. market could kind of continue unabated next year?

Sure. Well, obviously, the most important thing is having a great product with terrific clinical efficacy that makes a dramatic difference in patients' lives.

And if you know anybody who has got RA or serious psoriasis, which I'm sure you probably do, knowing you and how connected you are, that you can tell that the benefits are dramatic. You go from basically changing a person's life from a crippling disease to preventing that type of joint destruction that leads to that kind of incapacity, psoriasis the same way.

When you're talking about complete skin clearance for what is a pretty terrible and sometimes embarrassing disease, that's important. And then Crohn's also an insidious disease where you're changing someone's life.

And I don't think that people often appreciate that side of it that in many cases some of these diseases can lead to not only debilitating aspects, but also death in some cases. So you've got to have a very good product that makes a difference in people's lives, and that's what we have with HUMIRA, which is why the demand for it has been so strong.

There are... these are expensive drugs.

They are difficult to manufacture. And because of that, we try to do what we can on the patient side in terms of different programs, patients' assistance programs that will help certain economically disadvantaged patients with those co-pays and things that might be difficult for them to pay.

So we do what we can there to help them. But overall, it's really about changing the nature of this disease, the incident rates of the disease, the penetration rates and the overall profile globally of the product.

So with all those things set together, we expect there will be continued strong demand for HUMIRA over the next several years at a minimum.

And I have a couple of follow ups. Just quickly with regards to TRILIPIX, you've been very successful historically with managing the TriCor brand, going forward is the primary strategy, you're going to have the compatibility of TRILIPIX with statins and the lack of side effect profile with that drug in the label or might you consider actually removing TriCor from the market?

Well TRILIPIX does offer some significant advantages versus the older form of the product including TriCor. Recall that when we started out with this program, we had a plan to optimally design a compound that could be used in combination with statins safely and effectively.

That was the goal. We set out, we found a molecule here.

This is a different... it's a base form, but it's different, it's fenofibric acid which is designed for safe and effective use with combination with statins.

And that's what we showed in the three large clinical studies that were shown earlier this year. So we've got over 2700 patients in those trials.

We've demonstrated that in combination with those patterns you can have a dramatic impact on the outcome. And that's the most important thing we showed you can double the reduction in drugs, you can double the improvement in HDL the good cholesterol, and you can improve LDL all at the same time versus taking TriCor alone and or taking Niaspan alone.

So, and the safety was good, so you've got all of those aspects together, and so we will launch the TRILIPIX will TriCor on the market and we'll see how it goes and evaluate our options going forward.

Great. And my final questions change [ph].

As we have a very large number for your inflammatory franchise in 2012 north of $8 billion, almost $9 billion could you sort of scale for us the impact that, that might have on a basis point level for the operating margin in the pharma division. We have a tremendously in insurance [ph] drug everybody don't know what it is, the SG&A should be going down and manufacturing efficiency should be coming up.

Could you hazard any sort of gas?

Pretty hard to go out that far, but I think you've got the right turns that there, I mean this is a profitable product, that the ongoing SG&A investment is relatively stable and as volume goes down it should help the profitability of that business, so it's pretty hard to go out there as far in terms of really quantifying exactly what it means but directionally I think you're right.

Thank so much.

Thank you, operator. We'll take...

I think we have time for maybe two more questions.

Wachovia. Thanks for taking my question.

At first, John, I think you're close to your 12 months post launch XIENCE goal, almost like three months post launch. I think your goal was 25% to 30%.

Is that still your goal or are you going to increase that goal?

Well, that's an excellent question. We have a high class problem here.

We had it pretty early, didn't we? So it's...

XIENCE is doing exceptionally well as you know. We've already hit that goal.

If you look at the latest market share data, we're in the mid to high 20s for XIENCE only share in the U.S. already.

We do expect some steady improvement as I mentioned in that share. And hopefully we can get that closer to 30% or so as we exit the year.

So we're not updating that guidance right now, but obviously we're doing better than our expectations. The platform has done exceptionally well as you know and is more than 50% of the overall market.

I would say at this point we expect growth to continue next year, and this is going to be a significant product for us and we benefit from sales as well. So the platform is doing well, it will be larger next year, and we're obviously very pleased with that.

Great. Could you tell us what SIMCOR sales were in the quarter?

And based on the prescription data, it looks like in some of your earlier comments that SIMCOR hasn't met your expectations I think originally of 100 million in '08. What are you doing to improve its performance and can you remind us of the timing of the 40 milligram dose and the low flush version there?

And I just have one quick one after that.

Sure. Yes, SIMCOR, given the market dynamics that we've seen in the lipid market, it's below what we modeled initially.

But again, we're seeing more benefit with Niaspan. Niaspan is doing better than we expected.

And as we sell SIMCOR, we're selling the Niaspan molecule too. So we've seen Niaspan do well, we've seen TriCor do well.

Niaspan sales in a quarter were up more than 16%. So I think it's really just a function of the trajectory.

The curve has pushed back a little bit probably given the market dynamics, given ENHANCE [ph] and these various things that have affected, at least temporarily, how physicians and patients are viewing that. But it's still a great product as you know with strong clinical profile and we're working on a low flush form and that as well and...

but there is no specific timeline I can offer at this point. So we continue to work on that.

We expect the product to be a healthy sized product for us longer term. And in the meantime, our overall lipid franchise continues to do better than the market.

And the 30 milligram dose, John, I mean in the past, I think you were targeting 2009 launch, 40 milligrams I think about half of the simvastatin prescriptions today.

Yes, I don't have specific information on the 40 milligram. I'll have to get back to you on that just to get a more recent update on that, Larry.

Okay And just lastly, pediatric nutritionals in the U.S. was a little weaker than we expected and adult was stronger.

Was there anything unusual in those line items?

Yes, the only thing I would note is the comp issue really year-over-year for pediatric. We had big WIC accounts last year that impacted the overall year-over-year growth, but still strong.

And we are seeing very nice execution on some of the branded products in the domestic nutrition business on the adult side. And we've really picked up some share and grown the market and we are seeing some pretty nice results there.

Yes. And as I mentioned in my remarks too, Larry, recall, we've got a new package out.

I don't know if you have babies, but it's a very consumer friendly package with a lot of new ingredients that are specially designed for boosting the immune system. So that's off to a real strong start.

There is a lot of promotional effort behind that Ty Pennington from the TV fame is part of that program, and you can see all that on the website. So it's going pretty well.

I think we have time --

Thanks a lot.

Thanks Larry. We have time for one more question, operator.

Yes, Cowen and Company. Thanks for taking the question.

Good morning.

Let me go back to this TAP other income issue if I could. Tom, there's been a lot of variability in the three quarters that you're booking this this year.

And I'm just wondering as you go out to 2009, should we think about that being similarly up and down or volatile. And if you could just give us a sense for how much visibility you have into the quarterly fluctuations.

Well we have very good visibility. I mean it's basically, we know how the on-market products at Takeda Corp.

[ph] are doing, and we're aware of the development milestone activities. And as I have said more than once, as we look at those, we've been pretty conservative in forecasting those activities.

And the reason for the variability is these modest milestones have come from time to time and we just have to report... forecast them on a quarterly basis.

As you recall in the second quarter, we actually had one happen earlier than we thought and we had higher results. So there will be a degree of variability.

A little of that will continue in 2009. But again, we'll forecast conservatively and try to give you our best estimate of when they are going to occur so that you can do the appropriate modeling.

Yes. And Sara, I think I would add to that that we're...

we forecasted this when we split apart evenly the TAP joint venture. This was all in the pull apart and our forecast for the year.

So this is very consistent with what we've said from the beginning.

Okay. And in nutritionals, can you give us a status update on the Singapore manufacturing facility, when will that be on line and what should we expect in terms of how that could impact us, the costs and returns of that business?

That project has gone extremely well. It should be online in the first part of 2009, going through the final stages now.

It will be a very... a much more convenient way to supply the Asian market, which currently we're supplying in of our European facilities.

So, that's between the cost of materials and freight in the like [ph]. It will be a nice enhancement for the profile there.

It won't be a major mover, but it's just capacity we needed to supply the very strong demand for these product with some efficiencies and it just is a much more convenient to the markets.

And as such, tax advantage as well, Tom?

Yes.

Okay. And lastly, I [indiscernible] what you guys are assuming in terms of whether or not that products are need to scheduled?

Well, we're still on our goal and we're hoping it's a schedule free product, but that's up to the FDA. And, whether it schedule 2, or Schedule 3, we think it can be a significant product given all the things that discussed in my comments.

It's a large market, it's a well-known brand, it's a trusted brand that bring around the long time. This product offers some pretty unique benefits in terms of the dosing frequency down to one to two tablets a day and sustained blood levels and so forth.

So, whether it's two or three, it should be a significant product. There are some products that are too they have done quite well.

Obviously our goal would be to have a three but we're still expecting an approval here in the fourth quarter.

Okay. Thank you.

Thanks a lot. And that concludes our conference call.

A replay of the call will be available after 11 AM Central today on Abbott's Investor Relations website at abbottinvestor.com, and after 11 AM Central Time via telephone at 203-369-3520, confirmation code is 5567553. The audio replay will be available until 4 PM next Wednesday, October 22nd.

Thank you for joining us today.